Therapy for herpes simplex virus with emphasis on the role of foscarnet

    loading  Checking for direct PDF access through Ovid

Abstract

It is ironic that, as clinicians' confidence in the use of acyclovir as treatment and prophylaxis for cutaneous herpes simplex virus infection continues to increase, there is emerging evidence of developing viral resistance in immunosuppressed patients. Foscarnet is increasingly being successfully used to treat cases of suspected acyclovir-resistant herpes simplex virus infection but the development of other less toxic and orally bioavailable drugs is needed.

Related Topics

    loading  Loading Related Articles